This grant is a resubmission of a Core grant request for the University of Michigan Cancer Center. The application has been revised based on the suggestions of the previous NCI Center Support Review Committee. The University of Michigan Cancer Center (UMCC) was established by the Board of Regents in May 1986 to provide a focus for all of the cancer related activities throughout the University. The strategy of the Cancer Center is to provide an organizational framework to promote and enhance interdisciplinary research throughout the University. This is accomplished through the development of defined clinical and basic science interdisciplinary programs in cancer research and the development and support of shared core resources. There are seven clinical research programs in the UMCC. These represent coordinated research efforts in cancers of major organ systems including head and neck, breast, chest, genito-urinary, central nervous system, leukemia and lymphoma, and pediatric tumors. The six basic science research programs of the Center include tumor metastasis and the extracellular matrix, molecular mechanisms of gene regulation, tumor immunology, cancer pharmacology, drug development, and cancer epidemiology causation and prevention. The UMCC has established 10 shared core facilities which include a clinical trials office, biostatistics, tissue procurement, tumor imaging, pharmacokinetics, drug analysis, molecular biology, peptide synthesis, morphology and cytometry cores. The University has committed significant resources to the Cancer Center for the support of Center programs and shared core facilities. Dr. Wicha, Center Director, has responsibility for managing the affairs of the Center. He has authority and responsibility for space, equipment, budgets, and personnel assigned to the Center in addition to responsibility for coordinating Center Basic Research and Clinical Research Programs. The 216 faculty with appointments to the UMCC currently receive over 21 million dollars annually in grant support. The UMCC has had a major impact on cancer research at the University of Michigan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-03
Application #
3101841
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-09-30
Project End
1991-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605
Schofield, Heather K; Tandon, Manuj; Park, Min-Jung et al. (2018) Pancreatic HIF2? Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5:169-185.e2
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415

Showing the most recent 10 out of 1493 publications